Literature DB >> 22825027

Changes in the expression of cardiac mitofusin-2 in different stages of diabetes in rats.

Qin Gao1, Xiao-Mei Wang, Hong-Wei Ye, Ying Yu, Pin-Fang Kang, Hong-Ju Wang, Su-Dong Guan, Zheng-Hong Li.   

Abstract

The aim of this study was to investigate the role of mitofusin-2 (Mfn2) in different stages of diabetes in rats and to analyze the related mechanism(s). A diabetic model in SD rats was induced by a single intraperitoneal injection of 55 mg/kg streptozoticin (STZ). The hearts were isolated from diabetes mellitus (DM) rats at the fourth week (DM4W), eighth week (DM8W) and twelfth week (DM12W) and fasting blood glucose (FBG) levels and the ratio of heart weight to body weight (HW/BW) were measured. Malondialdehyde (MDA) content, superoxide dismutase (SOD) and caspase 3 activities were measured. The expression of Mfn2 of the left anterior myocardium at the mRNA level was detected using RT‑PCR. In contrast to the normal group, in the DM4W, DM8W and DM12W groups, there was a significant increase in the FBG levels, but no difference among the DM4W, DM8W and DM12W groups. The HW/BW ratio as well as the MDA content were increased, while SOD activity was reduced. Caspase‑3 activity was increased, while the expression of Mfn-2 mRNA levels was reduced. In addition, with the development of diabetic cardiomyopathy, the contents of MDA and caspase 3 were increased, whereas SOD activity and Mfn-2 mRNA levels were further reduced. In conclusion, our results indicated that with the development of diabetes, the expression of cardiac Mfn2 has showed a decrease, which may be associated with the decrease of antioxidant ability and progression of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22825027     DOI: 10.3892/mmr.2012.1002

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

Review 1.  Mitochondrial fission/fusion and cardiomyopathy.

Authors:  Dorn G W
Journal:  Curr Opin Genet Dev       Date:  2016-04-07       Impact factor: 5.578

2.  Triptolide improves systolic function and myocardial energy metabolism of diabetic cardiomyopathy in streptozotocin-induced diabetic rats.

Authors:  Zhongshu Liang; Sunnar Leo; Helin Wen; Mao Ouyang; Weihong Jiang; Kan Yang
Journal:  BMC Cardiovasc Disord       Date:  2015-05-13       Impact factor: 2.298

3.  Effects of hydrogen sulfide on inducible nitric oxide synthase activity and expression of cardiomyocytes in diabetic rats.

Authors:  Rui Yang; Qiang Jia; Xiao-Fen Liu; Yuan-Yuan Wang; Shan-Feng Ma
Journal:  Mol Med Rep       Date:  2017-08-14       Impact factor: 2.952

4.  Targeting mitochondrial dynamics by regulating Mfn2 for therapeutic intervention in diabetic cardiomyopathy.

Authors:  Lang Hu; Mingge Ding; Daishi Tang; Erhe Gao; Congye Li; Kaiyan Wang; Bingchao Qi; Jihuan Qiu; Huishou Zhao; Pan Chang; Feng Fu; Yan Li
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

5.  Mitochondrial dynamics and biogenesis indicators may serve as potential biomarkers for diagnosis of myasthenia gravis.

Authors:  Lanqi Li; Donghong Cai; Huiya Zhong; Fengbin Liu; Qilong Jiang; Jian Liang; Peiwu Li; Yafang Song; Aidong Ji; Wei Jiao; Jingwei Song; Jinqiu Li; Zhiwei Chen; Qing Li; Lingling Ke
Journal:  Exp Ther Med       Date:  2022-02-24       Impact factor: 2.447

Review 6.  Mitochondria-Endoplasmic Reticulum Contacts: The Promising Regulators in Diabetic Cardiomyopathy.

Authors:  Yan Chen; Yanguo Xin; Yue Cheng; Xiaojing Liu
Journal:  Oxid Med Cell Longev       Date:  2022-04-11       Impact factor: 7.310

Review 7.  Mitochondrial Arrest on the Microtubule Highway-A Feature of Heart Failure and Diabetic Cardiomyopathy?

Authors:  Sarah Kassab; Zainab Albalawi; Hussam Daghistani; Ashraf Kitmitto
Journal:  Front Cardiovasc Med       Date:  2021-07-02

Review 8.  The interplay between mitochondria and store-operated Ca2+ entry: Emerging insights into cardiac diseases.

Authors:  Jinliang Nan; Jiamin Li; Yinuo Lin; Muhammad Saif Ur Rahman; Zhengzheng Li; Lingjun Zhu
Journal:  J Cell Mol Med       Date:  2021-09-26       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.